Hakan YABANOGLU, Tevfik AVCI, Nazim Emrah KOCER, Ilker Murat ARER, Aydincan AKDUR, Abdirahman Sakulen HARGURA

Surgical therapy of medullary thyroid cancer and our clinical experiences

Aim: Medullary thyroid cancer (MTC) is a rare neuroendocrine tumor that originates from the thyroid parafollicular C cells and produces calcitonin. It is a quite aggressive disease with a potential to cause serious morbidity and mortality. In this study we aimed to report treatment outcomes of MTC, which has a bad prognosis and is difficult to manage.Material and Methods: The medical records of 1287 patients who were operated on for thyroid cancer between 2009 and 2018 were retrospectively assessed. Twenty-one patients (1.6%) were diagnosed with MTC.Results: Eleven (52.4%) patients were females. The age range of the patients was 54(14-85) years. Sixteen (76.2%) cases were sporadic and 5 (23.8%) were familial. Twelve patients underwent bilateral total thyroidectomy + central and unilateral neck dissection, 5(23.8%) bilateral total thyroidectomy + central and bilateral neck dissection, 4(19%) bilateral total thyroidectomy. Pathology examination revealed lymph node metastasis in 13(61.9%) patients. Three (14%) patients had simultaneous papillary thyroid cancer. Mean duration of follow-up was 52(3-96) months. Five (23.8%) patients suffered recurrence cervical lymph nodes (6 months later), lungs and bone metastasis (at 12th and 18th months), lungs (at 12thmonth), mediastinal lymph nodes (at 15th months), liver metastasis (at 6th months). Seven (33%) patients underwent chemo-radiotherapy.Conclusion: Surgery is the gold standard to control loco-regional disease and the only curative method among the available therapies in MTC treatment. Despite having a low incidence, MTC may still lead to serious mortality and morbidity in delayed cases and/or when loco-regional control cannot be achieved.

PDF

___

1. Kim BH, Kim IJ. Recent updates on the management of medullary thyroid carcinoma. Endocrinol Metab (Seoul) 2016;31:392-99.
2. Hazard JB, Hawk WA, Crıle G Jr. Medullary [solid] carcinoma of the thyroid: a clinicopathologic entity. J Clin Endocrinol Metab 1959;19:152-61.
3. Wells SA Jr, Asa SL, Dralle H, et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid 2015;25:567-610.
4. Aschebrook-Kilfoy B, Schechter RB, Shih YC, et al. The clinical and economic burden of a sustained increase in thyroid cancer incidence. Cancer Epidemiol Biomarkers Prev 2013;22:1252-9.
5. Ahn HS, Kim HJ, Welch HG. Korea’s thyroid-cancer “epidemic”: screening and overdiagnosis. N Engl J Med 2014;371:1765-7.
6. Kim TY, Kim WG, Kim WB, et al. Current status and future perspectives in differentiated thyroid cancer. Endocrinol Metab (Seoul) 2014;29:217-25.
7. Gilliland FD, Hunt WC, Morris DM, et al. Prognostic factors for thyroid carcinoma. A population-based study of 15,698 cases from the Surveillance, Epidemiology and End Results (SEER) program 1973-1991. Cancer 1997;79:564-73.
8. Hundahl SA, Fleming ID, Fremgen AM, et al. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995 [see commetns]. Cancer 1998;83:2638-48.
9. Burgess JR, Dwyer T, McArdle K, et al. The changing incidence and spectrum of thyroid carcinoma in Tasmania (1978-1998) during a transition from iodine sufficiency to iodine deficiency. J Clin Endocrinol Metab 2000;85:1513-7.
10. Lawal O, Agbakwuru A, Olayinka OS, et al. Thyroid malignancy in endemic nodular goitres: prevalence, pattern and treatment. Eur J Surg Oncol 2001;27:157-61.
11. From G, Mellemgaard A, Knudsen N, et al. Review of thyroid cancer cases among patients with previous benign thyroid disorders. Thyroid 2000;10:697-700.
12. Ménez C, Hu MI, Gagel RF. Management of medullary thyroid carcinoma. Endocrinol Metab Clin North Am 2008;37:481-96.
13. Koçak S, Özbaş S. Medüller tiroid kanseri. Türkiye Klinikleri J surg med Sci 2005;1:59-64.
14. Moley JF, DeBenedetti MK. Patterns of nodal metastases in palpable medullary thyroid carcinoma: recommendations for extent of node dissection. Ann Surg 1999;229:880-7.
15. Elisei R, Bottici V, Luchetti F, et al. Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer: experience in 10,864 patients with nodular thyroid disorders. J Clin Endocrinol Metab 2004;89:163-8.
16. Vierhapper H, Raber W, Bieglmayer C, et al. Routine measurement of plasma calcitonin in nodular thyroid diseases. J Clin Endocrinol Metab 1997;82:1589-93.
17. Costante G, Meringolo D, Durante C, et al.Predictive value of serum calcitonin levels for preoperative diagnosis of medullary thyroid carcinoma in a cohort of 5817 consecutive patients with thyroid nodules. J Clin Endocrinol Metab 2007;92:450-5.
18. Cheung K, Roman SA, Wang TS, et al. Calcitonin measurement in the evaluation of thyroid nodules in the United States: a cost-effectiveness and decision analysis. J Clin Endocrinol Metab 2008;93:2173-80.
19. Machens A, Dralle H. Biomarker-based risk stratification for previously untreated medullary thyroid cancer. J Clin Endocrinol Metab 2010;95:2655-63.
20. NCCN Clinical Practice Guidelines in Oncology Medullary thyroid carcinoma. 2016. https://www.nccn.org/professionals/physician_gls/pdf/thyroid.pdf.
21. Burinicardi F Charles Schwartz’s principels of surgery. In: Lal G, Clark HO. Thyroid, parathyroid, adrenal. McGraw Hill Company, Ninth Edition, Newyork, 2010:1343-408.
22. Ball WD. Medullary thyroid cancer: Monitoring and therapy. Endocrinol Metab Clin North Am 2007;36:823-37
23. Brierley JD, Tsang RW. External beam radiation therapy for thyroid cancer. Endocrinol Metab Clin North Am 2008;37:497-509.
24. Martinez SR, Beal SH, Chen A, et al. Adjuvant external beam radiation for medullary thyroid carcinoma. J Surg Oncol 2010;102:175-8.
25. Fife KM, Bower M, Harmer CL. Medullary thyroid cancer: the role of radiotherapy in local control. Eur J Surg Oncol 1996;22:588-91.
26. Terezakis SA, Lee NY. The role of radiation therapy in the treatment of medullary thyroid cancer. J Natl Compr Canc Netw 2010;8:532-40.
27. Brierley J, Tsang R, Simpson WJ, et al. Medullary thyroid cancer: analyses of survival and prognostic factors and the role of radiation therapy in local control. Thyroid 1996;6:305-10.
28. Konstantinidis A, Stang M, Roman SA, et al. Surgical management of medullary thyroid carcinoma. Updates Surg 2017;69:151-60.
29. Ismailov SI, Piulatova NR. Postoperative calcitonin study in medullary thyroid carcinoma. Endocr Relat Cancer 2004;11:357-63.
30. Elisei R, Pinchera A. Advances in the follow-up of differentiated or medullary thyroid cancer. Nat Rev Endocrinol 2012;8:466-75.
31. Lindsey SC, Ganly I, Palmer F, et al. Response to initial therapy predicts clinical outcomes in medullary thyroid cancer. Thyroid 2015;25:242-9.
32. Tuttle RM, Ganly I. Risk stratification in medullary thyroid cancer: moving beyond static anatomic staging. Oral Oncol 2013;49:695-701.
33. Yang JH, Lindsey SC, Camacho CP, et al. Integration of a postoperative calcitonin measurement into an anatomical staging system improves initial risk stratification in medullary thyroid cancer. Clin Endocrinol [Oxf] 2015;83:938-42.
34. Barbet J, Campion L, Kraeber-Bode´re´ F, et al. Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma. J Clin Endocrinol Metab 2005;90:6077-84.
35. Roman S, Lin R, Sosa JA. Prognosis of medullary thyroid carcinoma: demographic, clinical, and pathologic predictors of survival in 1252 cases. Cancer 2006;107:2134-42.
36. Veiga LH, Neta G, Aschebrook-Kilfoy B, et al. Thyroid cancer incidence patterns in Sao Paulo, Brazil, and the U.S. SEER program, 1997-2008 Thyroid 2013;23:748-57.
37. Machens A, Schneyer U, Holzhausen HJ, et al. Prospects of remission in medullary thyroid carcinoma according to basal calcitonin level. J Clin Endocrinol Metab 2005;90:2029-34.
38. Scollo C, Baudin E, Travagli JP, et al. Rationale for central and bilateral lymph node dissection in sporadic and hereditary medullary thyroid cancer. J Clin Endocrinol mETAB 2003;88:2070-5.
39. Machens A, Hauptmann S, Dralle H. Prediction of lateral lymph node metastases in medullary thyroid cancer. Br J Surg 2008;95:586-91.
40. Bumming P, Ahlman H, Nilsson B, et al. Can the early reduction of tumour markers predict outcome in surgically treated sporadic medullary thyroid carcinoma? Langenbecks Arch Surg 2008;393:699-703.
41. Pelizzo MR, Boschin IM, Bernante P, et al. Natural history, diagnosis, treatment and outcome of medullary thyroid cancer: 37 years experience on 157 patients. Eur J Surg Oncol 2007;33:493-7.